The stock exchanged hands 3.48 Million shares versus average trading capacity of 172.27 Million shares, yielding a market cap of $19.88 Million. Analysts have a mean recommendation of 2.30 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).
The company reported its last earnings Actual EPS of $-0.26/share.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) ended its day at $1.25 with the rising stream of 3.31% and its total traded volume was 3.48 million shares more than the average volume.
Price targets show what analysts believes a stock will be worth at the end of a certain time period.
Monahan's goal in OT leads Flames over Canadiens
The Flames had a chance for the lead with a two-man advantage for a full minute starting at the 12:47 mark but couldn't score. Calgary remains in search of its first win of the month after falling to 0-2-1 with Wednesday's 2-1 shootout loss at Toronto.
Moving average is significant analytical tool used to discover current price trends and the possibility for a change in an established trend.
The most recent non open market insider trade was completed by CARUSO JAMES V on 04/18/2017, and was a acquisition of 200,000 shares with a final price of $0.
The stock's current distance from 20-Day Simple Moving Average (SMA20) is -14.05% where SMA50 and SMA200 are -21.14% and -29.69% respectively. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued.
The company shows its Return on Assets (ROA) value of -75.4%.
Acordo alcançado garante ausência de fronteira física na Irlanda - May
O negociador-chefe da UE, Michel Barnier, considera que "serão protegidas as opções de vida dos cidadãos da UE que vivem no Reino Unido".
Return on Investment measures the amount of return on an investment relative to the investment's cost.
Insider Trading Activity for Cellectar Biosciences, Inc. In the past 3-month period alone, shares of CLRB have appreciated -0.36 - or -22.36%. An increasing ROE indicates that a company is improving its ability to make profit without requiring as much capital. The Return on Equity ratio of Cellectar Biosciences, Inc. The mean target projections are based on 1 opinions. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.6846451271156 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. The stock's 52-week range is $1.12 to $3.07, and its 3-month range is $1.12 to $2.04. It helps investors in determining whether buying, selling or holding on to a stock would be beneficial for them.
Cellectar Biosciences, Inc. (NASDAQ:CLRB), maintained return on investment for the last twelve months at -154.64, higher than what Reuters data shows regarding industry's average. While talking about Performance of the Stock, Cellectar Biosciences, Inc. now has a Weekly performance of -10.71%, monthly performance percentage is -18.83 percent, Quarterly performance is -19.87 percent, 6 months performance shows a percent value of -26.47% and Yearly Performance is -10.71 percent.
In IIT Delhi placements, 500 hired in first 5 days
Another student, Nikhil Chaturvedi, who got an offer with Microsoft in Redmond, US, said he was excited to start the job. Over 300 organisations across sectors offering over 500 job roles have already registered for placements.